Form 4 for CGEM Cullinan Therapeutics, Inc.
Accepted 2021-09-21 00:00:00 ET · period of report 2021-09-20 · accession 0000899243-21-036782 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-21 | 2021-09-20 | CGEM | Michaelson Jennifer | See Remarks | S - Sale+OE | $24.51 | -4,000 | 23.7K | -14% | -$98.0K |
| D | 2021-09-21 | 2021-09-20 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $4.30 | +4,000 | 26.9K | +17% | +$17.2K |
| D | 2021-09-21 | 2021-09-20 | CGEM | Michaelson Jennifer | See Remarks | M - OptEx | $0.00 | -4,000 | 222.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-20 | S | D | 800 | $25.20 | 22,911 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.95 to $25.48. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2021-09-20 | M | A | 4,000 | $4.30 | 26,911 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-20 | S | D | 3,200 | $24.34 | 23,711 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.92 to $24.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 4 | Derivative | Stock Option (Right to Buy) | 2021-09-20 | M | D | 4,000 | $0.00 | 221,978 | D | $4.30 · — to 2030-10-28 | 4,000 Common Stock | (F4) 25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |